Disruptive Innovation: Success Breeds Longevity

Disruptive innovations in health care are often the drivers of new technologies and new treatments that enhance and build upon old modalities. The birth of osteopathic medicine in the 1870s can be seen as a “disruptive innovation” in its revolutionary approach to medical treatment.

Castellani: A Long-term Vision for Innovative Biopharmaceutical Research Sector Needed

04.11.13 | By

John Castellani, PhRMA’s president & CEO, opened today’s afternoon session of PhRMA’s Annual Meeting in San Diego in a speech calling on policymakers, healthcare stakeholders, biopharmaceutical industry critics and sector allies alike to recognize and leverage the value of innovative medicines.

PhRMA’s Contributions to The Fight Against Chronic Diseases

04.11.13 | By

According to the Kaiser Family Foundation, health care expenditures in the United States approached $2.6 trillion in 2010, over ten times the $256 billion spent in 1980. 

The expectation this year: Americans will spend $2.9 trillion on health care.  And federal, state and local government agencies are in overdrive to find the best ways to reduce costs and still maintain quality patient care.  

John Castellani 2013 Annual Meeting Remarks

 Good afternoon and welcome back. I hope you enjoyed lunch and Dan Pink’s thought-provoking talk.

 We at PhRMA are thrilled to be in San Diego for this year’s meeting.

 I want to thank John Lechleiter and the Eli Lilly team for their work and contributions to this meeting. I also want to thank all the PhRMA Board Members and especially our incoming chairman Bob Hugin of Celgene who inherits the challenge of overseeing next year’s meeting.

Rx Minute: Implementation of Medicare Part D Followed by Significant Reductions in Nondrug Medical Spending

new study published in the Journal of the American Medical Association (JAMA) finds that implementation of the Medicare prescription drug plan in 2006 was followed by significant decreases in spending on nondrug medical expenditures among beneficiaries who previously had limited drug coverage. After Medicare Part D started, nondrug medical spending in this group was about $1,200 per year less than expected.

Rx Minute: Insurance Coverage for Chronically Ill Less Generous

recent study found that insurance coverage for chronically ill patients is less generous than those without a chronic condition, primarily due to higher cost sharing for prescription drugs. 

“We Work for Health” Champions

04.11.13 | By

There is certainly no lack of talent in the biopharmaceutical industry. Every day, employees are working hard in a variety of roles to ensure that patients get the treatments they need. It isn’t just the research scientists in the lab, it’s sales executives and communications staff who go above and beyond to advance research, progress and hope in everything they do.

Rx Minute: Statins Value to Society & Risk Factors Linked to Alzheimer's

A recent article published in Health Affairs highlights the remarkable impact of cholesterol-lowering drugs known as statins on the treatment of cardiovascular disease in the U.S.

Research Key to Medical “Miracles”

04.11.13 | By

The second #PhRMA13 panel begins at 1:45 pm EDT and will address medical breakthroughs and what needs to change to speed personalized medicine to patients. In a guest post, John Crosby, Executive Director at the American Osteopathic Association, addresses what he believes is necessary to bring science from the lab to the patient.

Pivotal Time for U.S. Biopharmaceutical Industry

04.11.13 | By

PhRMA Chairman and Lilly President and CEO John Lechleiter is kicking off #PhRMA13 now. In a guest post he discusses the future of the industry. To learn more watch live now!

For decades, San Diego has been at the center of the biotech revolution. The advances pioneered by scientists in the San Diego area have had a dramatic impact on human well-being and longevity. 

Pages

Subscribe to RSS - Opinion